Global X China Biotech ETF (HKG:2820)
Hong Kong · Delayed Price · Currency is HKD 64.50
-1.80 (-2.71%)
Mar 4, 2026, 3:55 PM HKT
28.69% (1Y)
| Assets | 642.77M |
| Expense Ratio | 0.68% |
| PE Ratio | 45.34 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +28.69% |
| Volume | 77,926 |
| Open | 65.52 |
| Previous Close | 66.30 |
| Day's Range | 63.72 - 65.62 |
| 52-Week Low | 44.40 |
| 52-Week High | 84.50 |
| Beta | 0.52 |
| Holdings | 43 |
| Inception Date | Jul 25, 2019 |
About 2820
The Global X China Biotech ETF seeks to provide investment results that, before deduction of fees and expenses, closely correspond to the performance of the Underlying Index.
Asset Class Equity
Category Health Care
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2820
Provider Global X
Index Tracked Solactive China Biotech Index
Performance
2820 had a total return of 28.69% in the past year, including dividends. Since the fund's inception, the average annual return has been 1.87%.
Top 10 Holdings
84.53% of assets| Name | Symbol | Weight |
|---|---|---|
| WuXi Biologics (Cayman) Inc. | 2269 | 14.00% |
| Innovent Biologics, Inc. | 1801 | 12.28% |
| BeOne Medicines AG | ONC | 12.13% |
| WuXi AppTec Co., Ltd. | 603259 | 9.45% |
| Akeso, Inc. | 9926 | 8.58% |
| Jiangsu Hengrui Pharmaceuticals Co.,Ltd | 600276 | 8.43% |
| Sino Biopharmaceutical Limited | 1177 | 7.02% |
| 3SBio Inc. | 1530 | 5.03% |
| Hansoh Pharmaceutical Group Company Limited | 3692 | 4.96% |
| XtalPi Holdings Limited | 2228 | 2.64% |